For complete information about the report, please visit our website
https://www.reportscorner.com/reports/28665/-Celgene-(CELG)---Label-Expansion-of-Marketed-Product-and-Newly-Drug-launches---Maturing-Pipeline---Long-Term-Gain/
CELG’s Maturing pipeline through its own proprietary compounds and acquisition/in-licensing should keep the momentum positively in coming years. New launches – POMALYST (L, Pomalidomide, RRMM), Apremilast (PR, Psoriasis, PsA), and label and geographic expansion of marketed products – Revlimid, Vidaza, and ABRAXANE (L, mBC, NSCLC; R – pancreatic cancer, PDUFA: Sept. 21, 2013) should sustain the growth for long term. CELG has recently raised $1.5b in senior notes strengthening its balance sheet and continues it buyback plans ($3b announced in June 2013). We expect ... For more detail please read our report on Celgene released on 2nd Sept. 2013, titled, "Label Expansion of Marketed Product and Newly Drug launches + Maturing Pipeline = Long Term Gain".
https://www.reportscorner.com/reports/28665/-Celgene-(CELG)---Label-Expansion-of-Marketed-Product-and-Newly-Drug-launches---Maturing-Pipeline---Long-Term-Gain/
CELG’s Maturing pipeline through its own proprietary compounds and acquisition/in-licensing should keep the momentum positively in coming years. New launches – POMALYST (L, Pomalidomide, RRMM), Apremilast (PR, Psoriasis, PsA), and label and geographic expansion of marketed products – Revlimid, Vidaza, and ABRAXANE (L, mBC, NSCLC; R – pancreatic cancer, PDUFA: Sept. 21, 2013) should sustain the growth for long term. CELG has recently raised $1.5b in senior notes strengthening its balance sheet and continues it buyback plans ($3b announced in June 2013). We expect ... For more detail please read our report on Celgene released on 2nd Sept. 2013, titled, "Label Expansion of Marketed Product and Newly Drug launches + Maturing Pipeline = Long Term Gain".
No comments:
Post a Comment